Education and Counseling Checklist for Pharmacies

THALOMID Risk Evaluation and Mitigation Strategy (REMS)™ program (formerly known as the S.T.E.P.S.® program) education and prescribing safety

Authorization No.: Confirmation No.: Confirmation Date:

Pharmacy Name:

Pharmacy Address:

Counselor Name: Work Phone: Ext.:

Patient Name: Date of Birth:

Risk Category:

Checklist for female patients of reproductive potential

☐ I will make sure that patients are aware that they will receive the Medication Guide along with their prescription

I COUNSELED ADULTS AND CHILDREN ON:

☐ Potential embryo-fetal toxicity

☐ Not taking THALOMID® (thalidomide) if pregnant or breastfeeding

☐ Using at the same time at least 1 highly effective method—tubal ligation, IUD, hormonal (birth control pills, hormonal patches, injections, vaginal rings, or implants), or partner’s vasectomy—and at least 1 additional effective method of birth control—male latex or synthetic condom, diaphragm, or cervical cap—every time they have sex with a male, or abstaining from sex with a male

☐ Continuing to use at the same time at least 1 highly effective method and at least 1 additional effective method of birth control beginning at least 4 weeks before taking THALOMID, while taking THALOMID, during dose interruptions, and for at least 4 weeks after stopping THALOMID every time they have sex with a male, or abstaining from sex with a male

☐ Obtaining a pregnancy test—performed by their healthcare provider—weekly during the first 4 weeks of use. Thereafter, pregnancy testing should be repeated every 4 weeks during the rest of their treatment in females with regular menstrual cycles or no cycle at all. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks

Reference ID: 3838532
The need to stop taking THALOMID right away in the event of becoming pregnant, or if they think for any reason they may be pregnant, and to call their healthcare provider immediately

Possible side effects include deep vein thrombosis and pulmonary embolism

Not sharing THALOMID capsules with anyone—especially with females who can get pregnant

Not donating blood while taking THALOMID (including dose interruptions) and for 4 weeks after stopping THALOMID

Not breaking, chewing, or opening THALOMID capsules

Instructions on THALOMID dose and administration

Milligram (mg) Strength_______ Number of Capsules Dispensed________________

FEMALE CHILDREN (<18 YEARS OF AGE):

Parent or legal guardian must have read the THALOMID REMS™ education material and agreed to ensure compliance

Checklist for female patients not of reproductive potential (natural menopause for at least 24 consecutive months, a hysterectomy, and/or bilateral oophorectomy)

I will make sure that patients are aware that they will receive the Medication Guide along with their prescription

I COUNSELED ADULTS AND CHILDREN ON:

Possible side effects include deep vein thrombosis and pulmonary embolism

Not sharing THALOMID capsules with anyone—especially with females who can get pregnant

Not donating blood while taking THALOMID (including dose interruptions) and for 4 weeks after stopping THALOMID

Not breaking, chewing, or opening THALOMID capsules
Instructions on THALOMID dose and administration

Milligram (mg) Strength_________ Number of Capsules Dispensed_________

FEMALE CHILDREN (<18 YEARS OF AGE):

☐ Parent or legal guardian must have read the THALOMID REMS™ education material and agreed to ensure compliance

☐ Parent or legal guardian must inform the child’s doctor when the child begins menses

Checklist for male patients

☐ I will make sure that patients are aware that they will receive the Medication Guide along with their prescription

I COUNSELED ADULTS AND CHILDREN ON:

☐ Potential embryo-fetal toxicity and contraception (wearing a latex or synthetic condom every time when engaging in sexual intercourse with a female who can get pregnant)

☐ Female partners of males taking THALOMID® (thalidomide) must call their healthcare provider right away if they get pregnant

☐ Possible side effects include deep vein thrombosis and pulmonary embolism

☐ Not sharing THALOMID capsules with anyone—especially with females who can get pregnant

☐ Not donating blood or sperm while taking THALOMID (including dose interruptions) and for 4 weeks after stopping THALOMID

☐ Not breaking, chewing, or opening THALOMID capsules

☐ Instructions on THALOMID dose and administration

Milligram (mg) Strength_________ Number of Capsules Dispensed_________

MALE CHILDREN (<18 YEARS OF AGE):

☐ Parent or legal guardian must have read the THALOMID REMS™ education material and agreed to ensure compliance
All boxes and spaces must be marked or filled in during counseling with the patient for every prescription.

Counselor Signature: ________________________ Date: _______________

For more information about THALOMID and the THALOMID REMS™ program, please visit www.CelgeneRiskManagement.com, or call the Celgene Customer Care Center at 1-888-423-5436.

Celgene Corporation
86 Morris Ave
Summit, NJ 07901

THALOMID is only available under a restricted distribution program, THALOMID REMS™.

Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS, enclosed.

THALOMID® is a registered trademark of Celgene Corporation. THALOMID REMS™ is a trademark of Celgene Corporation.

© 2013 Celgene Corporation 12/13 REMS-THA13346